Clinical trials: sponsored by Shanghai JMT-Bio Inc.
Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with…
- Trial name
- NCT06892431
- Testing
- Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine
- Volunteers
- 150 people
- Sponsor
- Shanghai JMT-Bio Inc.
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.
- Trial name
- NCT06846437
- Testing
- JSKN003, Trastuzumab emtansine (T-DM1)
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Shanghai JMT-Bio Inc.
Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed…
- Conditions
- Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC
- Trial name
- NCT06735391
- Testing
- JMT101, Osimertinib
- Where
- China
- Volunteers
- 516 people
- Sponsor
- Shanghai JMT-Bio Inc.
B-cell Non Hodgkin Lymphoma
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
This is a Phase 1, open-label, multi-center study to evaluate the safety of JMT601 in the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma and to determine the recommended dose for Phase 2 studies…
- Trial name
- NCT06725524
- Testing
- JMT601
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Shanghai JMT-Bio Inc.
Healthy Subjects
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JMT202 in Healthy Participants.
- Trial name
- NCT06564467
- Testing
- JMT202, Placrbo
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
This was a multicenter, open-label phase 2 study. This study aimed to evaluate the efficacy and safety of JMT101 combined with Osimertinib in participants with local advanced or metastatic non-small-cell lung cancer harbouring…
- Trial name
- NCT06391944
- Testing
- JMT101 Injection, Osimertinib tablet
- Where
- China
- Volunteers
- 161 people
- Sponsor
- Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
This is a multicenter, randomized, open-label, parallel-controlled phase 3 study. This study aims to evaluate the efficacy and safety of JMT101 combined with Osimertinib compared with Cisplatin combined with pemetrexed in…
- Trial name
- NCT06380348
- Testing
- JMT101 Injection, Osimertinib tablet, Cisplatin injection
- Volunteers
- 398 people
- Sponsor
- Shanghai JMT-Bio Inc.
Squamous Cell Non-small Cell Lung Cancer
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell…
- Trial name
- NCT06319313
- Testing
- JMT101, docetaxel, HB1801
- Volunteers
- 534 people
- Sponsor
- Shanghai JMT-Bio Inc.
Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid
This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors.
- Trial name
- NCT06221072
- Testing
- JMT103, zoledronic acid
- Volunteers
- 1,360 people
- Sponsor
- Shanghai JMT-Bio Inc.
Stomach Cancer
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together.
- Trial name
- NCT05427383
- Testing
- KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Shanghai JMT-Bio Inc.
Bone Metastases From Solid Tumors
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.
- Trial name
- NCT04630522
- Testing
- Drug: JMT103- 120 mg SC Q4W, Drug: JMT103- 120 mg SC Q8W, Drug: JMT103- 180 mg SC Q8W
- Where
- China
- Volunteers
- 295 people
- Sponsor
- Shanghai JMT-Bio Inc.
Metastatic Colorectal Cancer (mCRC)
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer…
- Trial name
- NCT06089330
- Testing
- JMT101, SG001, Irinotecan
- Volunteers
- 102 people
- Sponsor
- Shanghai JMT-Bio Inc.
Giant Cell Tumor of Bone
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
This is a phase Ⅲ, multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of narlumosbart (JMT103) in patients with unresectable or surgically difficult giant cell tumor of bone…
- Trial name
- NCT05813665
- Testing
- Narlumosbart, Denosumab
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Shanghai JMT-Bio Inc.
Giant Cell Tumor of Bone
Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone
This is a phase Ib/II, multicenter, single-arm, open-label study to evaluate the efficacy and safety of JMT103 in patients with surgically unsalvageable or refractory giant cell tumor of bone (GCTB).
- Trial name
- NCT04255576
- Testing
- Dietary Supplement: Calcium/Vitamin D
- Where
- China
- Volunteers
- 139 people
- Sponsor
- Shanghai JMT-Bio Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.
- Trial name
- NCT05513664
- Testing
- Osimertinib
- Where
- 24 sites in China
- Volunteers
- 80 people
- Sponsor
- Shanghai JMT-Bio Inc.
Postmenopausal Osteoporosis
Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.
- Trial name
- NCT05278338
- Testing
- JMT103, Denosumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Giant Cell Tumor of Bone
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
This is a retrospective observational real-world study, which evaluates the efficacy and safety of denosumab and non-denosumab therapies in the treatment of Chinese populations of surgically unsalvageable or severe post-surgery…
- Trial name
- NCT05402865
- Testing
- Denosumab
- Where
- 3 sites in China
- Volunteers
- 301 people
- Sponsor
- Shanghai JMT-Bio Inc.
Glucocorticoid Induced Osteoporosis
Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis
This is a randomized, double-blind, double-dummy, positive-controlled phase II interventional study designed to evaluate the efficacy and safety of JMT103 in the treatment of glucocorticoid induced osteoporosis patients.
- Trial name
- NCT05397938
- Testing
- JMT103, Alendronate sodium
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Shanghai JMT-Bio Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR…
- Trial name
- NCT05132777
- Testing
- JMT101, Osimertinib Mesylate Tablets
- Volunteers
- 155 people
- Sponsor
- Shanghai JMT-Bio Inc.
Advanced Solid Tumor
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.
- Trial name
- NCT04689100
- Testing
- JMT101
- Where
- 9 sites in China
- Volunteers
- 259 people
- Sponsor
- Shanghai JMT-Bio Inc.